Clinical Trials Logo

IGA Nephropathy clinical trials

View clinical trials related to IGA Nephropathy.

Filter by:

NCT ID: NCT01538433 Completed - IgA Nephropathy Clinical Trials

A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy

Start date: February 2012
Phase: N/A
Study type: Observational

This is a survey of factors which affect a pathologically defined early or delayed diagnosis of IgA nephropathy in Guangdong General Hospital, Guangzhou, China. An early or delayed diagnosis of IgA nephropathy is pathologically defined using the recently published Oxford classification of IgA nephropathy. The factors to be surveyed include health examination including urine test, socioeconomic status of patients including education,etc.

NCT ID: NCT01502579 Completed - IgA Nephropathy Clinical Trials

An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

Start date: September 2011
Phase: N/A
Study type: Observational

The pathological variants of IgA nephropathy identified by the Oxford classification may be related to the clinical data at presentation and follow-up, including proteinuria and renal function. This study is aimed to identify the potential relationship between pathological variants and clinical data in IgA nephropathy.

NCT ID: NCT01451710 Completed - IgA Nephropathy Clinical Trials

The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Start date: March 2011
Phase: N/A
Study type: Interventional

This is a single center,prospective,no-controlled clinical trial

NCT ID: NCT01392833 Completed - Clinical trials for Chronic Kidney Disease

Steroids and Azathioprine in Advanced IgAN

Start date: December 1999
Phase: Phase 3
Study type: Interventional

Some years ago the investigators designed a randomised trial to prospectively evaluate whether adding low-dose azathioprine (1.5 mg/kg/day for six months) to steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) can improve long-term renal survival in adult IgAN patients with proteinuria higher than 1g/24 hours and plasma creatinine <=2.0 mg/dl. In order to test the efficacy of the combination of steroids with azathioprine at various degree of renal function deterioration by extending the trial to patients with more advanced disease (serum creatinine higher or equal to 2 mg/dl) without any time limit for renal biopsy. Treatment will last one year: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months, then 0.2 mg/kg every other day for further 6 months. The primary outcome was renal survival (a 50% increase in plasma creatinine from baseline); the secondary outcomes were proteinuria over time and the number and types of adverse events in the two groups assessed every month for the first six months, every two months from the 6th to the 12th month and every three months thereafter. The planned duration of follow up is five years.

NCT ID: NCT01237028 Completed - IgA Nephropathy Clinical Trials

Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System Blockers

Start date: March 2011
Phase: N/A
Study type: Interventional

This study will help to show the efficacy of vitamin D and address the optimal strategy to minimize renal injury in IgAN patients.

NCT ID: NCT01224028 Completed - IgA Nephropathy Clinical Trials

A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study is to evaluate efficacy and safety of tacrolimus in the patients with non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with tacrolimus (Prograf) or placebo.

NCT ID: NCT01203007 Not yet recruiting - IGA Nephropathy Clinical Trials

Diet Intervention in Food Sensitive Patients With IgA Nephropathy

DIIGA
Start date: September 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to assess whether a tailored diet, eliminating antigens to which IgA nephropathy patients have demonstrated sensitivity, will have an effect on proteinuria, renal function and other immunological variables.

NCT ID: NCT01129557 Terminated - Clinical trials for Diabetic Nephropathy

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Start date: September 2009
Phase: Phase 4
Study type: Interventional

Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months). The investigators hypothesize that aldosterone breakthrough occurs due to accumulation of active precursor substances, most notably angiotensin II, produced in response to conventional RAAS blockade with ACEinhibitors and ARBs. The investigators believe that direct renin inhibition (DRI) should minimize this accumulation and therefore significantly lower or possibly eliminate the breakthrough effect. Interruption of the renin-angiotensin-aldosterone system (RAAS) with angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs), alone and in combination, has become a leading therapy to slow the progression of chronic heart and kidney disease. Both types of drugs inhibit the formation of aldosterone, a hormone, which has been shown to have harmful effects on patients with chronic heart and kidney disorders. This treatment is effective but not perfect since, even after an initial improvement, many patients become worse over the long term. This may be due to an unexpected increase in aldosterone, a phenomenon called "aldosterone breakthrough." The purpose of this study is to find out whether the use of a direct renin inhibitor (DRI) alone, or in combination with an angiotensin receptor blocker (ARB), will lessen the occurrence of aldosterone breakthrough since direct renin inhibitors inhibit the formation of aldosterone at a very early step. This study will compare the effectiveness of adding Diovan (valsartan) or Tekturna (aliskiren) or a combination of Diovan and Tekturna to the usual antihypertensive treatment. The investigators will follow blood pressure, aldosterone levels, and urinary protein levels over 9 months to evaluate which of these therapies is most effective for treating hypertension in patients with proteinuric kidney disease.

NCT ID: NCT01103778 Completed - Clinical trials for Chronic Kidney Disease

Pilot Study of Velcade® in IgA Nephropathy

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.

NCT ID: NCT00922311 Completed - IgA Nephropathy Clinical Trials

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Start date: July 2009
Phase: Phase 4
Study type: Interventional

Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk of developing progressive renal failure.